RESEARCH · TESAMORELIN 5MG · HEPATIC OMICS
Tesamorelin and the Liver at the Molecular Level: Hepatic Transcriptomics, Plasma Proteomics, Immune Markers and the IGF Axis
PurixLab’s Tesamorelin 5mg vial contains tesamorelin, a synthetic analogue of growth hormone-releasing hormone (GHRH). Earlier articles in this series covered visceral fat and liver fat trials, pharmacokinetics and GH pulsatility and long-term safety data. This overview asks a narrower question: what did the molecular follow-up studies of one liver trial report? Researchers used stored liver biopsies and plasma samples from that trial for gene-expression, proteomic and growth-factor analyses. All the work below used clinical-grade tesamorelin in people with HIV under trial protocols. The findings are reported as the authors described them. They are not claims about any PurixLab product, and the vial is for laboratory research use only.
The trial behind the samples
The source cohort is a randomised, double-blind, placebo-controlled study. It enrolled 61 people with HIV and a hepatic fat fraction of 5% or more on proton magnetic resonance spectroscopy, randomised them to tesamorelin or placebo for 12 months, and took liver biopsies at baseline and at the end of that period [1]. The authors reported an absolute between-group difference in hepatic fat fraction of -4.1%, a relative reduction from baseline of -37%, and fasting glucose and glycated haemoglobin changes that did not differ between groups at 12 months [1]. An earlier six-month, single-centre trial in 50 participants had reported modest liver-fat reductions alongside visceral fat changes [2]. Because the larger trial collected paired biopsies, the same participants could later be studied at the level of tissue transcripts and circulating proteins. That is unusual for a GHRH-analogue programme.
Hepatic transcriptomics on paired biopsies
Fourman and colleagues applied gene set enrichment analysis to RNA from the paired biopsies [3]. Compared with placebo, they reported higher hepatic expression of hallmark gene sets for oxidative phosphorylation and lower expression of gene sets for inflammation, tissue repair and cell division. They also reported reciprocal shifts in curated gene sets that other studies had linked to favourable or poor hepatocellular carcinoma prognosis. Among tesamorelin-treated participants, these expression changes correlated with a fibrosis-related gene score [3].
These are bulk-tissue, pathway-level signals. They do not show which liver cell types changed. The prognosis gene sets came from cancer cohorts, so a shift in those signatures is a molecular association, not a measured clinical outcome.
From transcripts to plasma proteins
A follow-up study measured 9 plasma proteins chosen because they matched top leading-edge genes in the differentially regulated gene sets [4]. Compared with placebo, the authors reported reductions in vascular endothelial growth factor A (VEGFA, P = 0.02), transforming growth factor beta 1 (TGFB1, P = 0.05) and macrophage colony-stimulating factor 1 (CSF1, P = 0.004). In the tesamorelin group, falls in VEGFA (r = 0.62) and CSF1 (r = 0.50) correlated with a decline in NAFLD activity score, and falls in TGFB1 (r = 0.61) and CSF1 (r = 0.64) tracked a lower gene-level fibrosis score [4]. Because CSF1 regulates monocyte recruitment and activation, the authors suggested it deserves further study in HIV-associated NAFLD.
Circulating immune-activation markers
A broader panel looked at 92 biomarkers of immunity, chemotaxis and metabolism in plasma from the 61 trial participants [5]. The authors reported that 13 proteins decreased significantly with tesamorelin compared with placebo, and that none increased. The 13 included 4 chemokines (CCL3, CCL4, CCL13 and IL-8), 2 cytokines (IL-10 and CSF-1), 4 T-cell-associated molecules (CD8A, CRTAM, GZMA and ADGRG1), and ARG1, galectin-9 and HGF. Network analysis grouped these proteins into closely related immune pathways. Targeted transcriptomics on liver tissue showed a matching signal of down-regulated immune-activation pathways [5].
A proteomic signature of fibrosis
Another analysis of the same cohort studied the disease rather than the drug. Using two high-multiplex panels, the investigators measured 183 plasma proteins at baseline and at 12 months [6]. They found 20 proteins up-regulated at baseline in participants with fibrosis stages 2-3 compared with stages 0-1. The most differentially expressed were matrix metalloproteinase 2, IGF-binding protein 7 and the collagen α1(I) chain, and the pathways included the response to tumour necrosis factor and aminopeptidase activity. In the placebo arm, 11 proteins rose further in participants whose fibrosis progressed over 12 months [6].
A companion paper described the natural history in the same trial. Of the 58 participants with baseline biopsies, 43% had hepatic fibrosis. Among the 24 placebo participants with paired biopsies, 38% showed fibrosis progression over 12 months. Each 25 cm² of additional baseline visceral fat was associated with an odds ratio of 1.37 for progression [7].
The IGF axis and FGF21
RNA sequencing data were available from the biopsies of 39 participants [8]. The authors reported that hepatic IGF1 mRNA was lower in participants with more steatosis and higher NAFLD activity scores, and was inversely related to glucose measures independent of circulating IGF-1. IGFBP6 and IGFBP7 expression rose with steatosis, and IGFBP7 also rose with fibrosis. In the randomised comparison, the GHRH analogue increased circulating IGFBP-1 and IGFBP-3 and decreased IGFBP-2 and IGFBP-6 [8].
The earlier six-month trial was used to look at fibroblast growth factor 21 (FGF21). At baseline, log FGF21 was associated with log liver fat (r = 0.32). FGF21 tended to fall with tesamorelin compared with placebo (p = 0.06), and across the cohort, falls in FGF21 tracked reductions in liver fat, GGT and the FIB-4 index [9]. The authors concluded that the liver-fat change ran through pathways other than an increase in serum FGF21. Separately, a pooled analysis of 806 phase III participants reported larger ALT and AST reductions over 26 weeks in visceral-fat responders than in non-responders among those with baseline transaminases above 30 U/l [10].
Reading the omics series critically
- One trial, many analyses. The transcriptomic, proteomic, immune-marker and IGF-binding-protein papers all draw on the same 61-participant trial, so they are not independent replications [1,3,4,5,8].
- Association is not mechanism. The correlations between plasma proteins, gene scores and histology are hypothesis-generating. The authors did not test causal pathways experimentally.
- Population-specific context. A 2025 review describes steatotic liver disease in people with HIV as having distinct drivers, including chronic immune activation, gut permeability and antiretroviral therapy, so these results may not transfer to other groups [11].
- Disclosed interests. Several papers in the series disclose author consulting for the drug’s developer and an institutional royalty agreement [3,4].
- Trial material is not a research vial. Each study used clinical-grade tesamorelin under a registered protocol. None of these results describes PurixLab stock.
Tesamorelin 5mg at PurixLab
Tesamorelin 5mg: a labelled lyophilized research vial with 5mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. It is not the clinical-grade material used in the studies above. The product page does not currently show a certificate of analysis. If your project needs particular supporting documentation, email [email protected] before ordering and tell us what you need. Product page: purixlab.com/product/tesamorelin-5mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout). Current offers are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PubMed 31611038 · PMC6981288 · doi:10.1016/S2352-3018(19)30338-8
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9. PubMed 25038357 · PMC4363137 · doi:10.1001/jama.2014.8334
- Fourman LT, Billingsley JM, Agyapong G, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16):e140134. PubMed 32701508 · PMC7455119 · doi:10.1172/jci.insight.140134
- Fourman LT, Stanley TL, Billingsley JM, et al. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Sci Rep. 2021;11(1):10485. PubMed 34006921 · PMC8131688 · doi:10.1038/s41598-021-89966-y
- Stanley TL, Fourman LT, Wong LP, et al. Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021;73(4):621-630. PubMed 33852720 · PMC8366828 · doi:10.1093/cid/ciab019
- Fourman LT, Stanley TL, Ockene MW, et al. Proteomic Analysis of Hepatic Fibrosis in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease Demonstrates Up-regulation of Immune Response and Tissue Repair Pathways. J Infect Dis. 2023;227(4):565-576. PubMed 36461941 · PMC10152500 · doi:10.1093/infdis/jiac475
- Fourman LT, Stanley TL, Zheng I, et al. Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021;72(12):2087-2094. PubMed 32270862 · PMC8204775 · doi:10.1093/cid/ciaa382
- Stanley TL, Fourman LT, Zheng I, et al. Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2021;106(2):e520-e533. PubMed 33125080 · PMC7823253 · doi:10.1210/clinem/dgaa792
- Braun LR, Feldpausch MN, Czerwonka N, et al. Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation. Growth Horm IGF Res. 2017;37:1-6. PubMed 29031905 · PMC5705434 · doi:10.1016/j.ghir.2017.10.002
- Fourman LT, Czerwonka N, Feldpausch MN, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(16):2253-2259. PubMed 28832410 · PMC5633509 · doi:10.1097/QAD.0000000000001614
- Gattu AK, Fourman LT. Metabolic dysfunction-associated steatotic liver disease in people with HIV. Curr Opin HIV AIDS. 2025;20(4):350-358. PubMed 40397552 · PMC12314779 · doi:10.1097/COH.0000000000000952